Novo Nordisk’s Hemophilia Breakthrough Fails to Distract From Canadian Generic Blow
Novo Nordisk’s stock slides 41% as Canada approves first generic Ozempic, while promising hemophilia data fails to lift…
Novo Nordisk’s Teen Pill Breakthrough and Canadian Generic Blow Arrive in the Same Week
Novo Nordisk faces a historic Ozempic generic in Canada while scoring a first-in-class oral GLP-1 win for teens,…